1312

MULTIPLEX BIOMARKER SERUM ASSAY DETECTS EARLY PANCREATIC ADENOCARCINOMA IN HIGH-RISK PATIENTS

Date
May 21, 2024
Explore related products in the following collection:

Background:
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed after reaching an advanced stage. High-risk patients with genetic predisposition (ie. BRCA2, CHEK-2 mutations), family history of pancreatic cancer (FPC), or high-risk intraductal papillary mucinous neoplasm (IPMN) could benefit from additional screening. However, optimal screening for high-risk patients has not been established. Biomarker assays have been validated on patients with known PDAC and healthy controls but not for primary screening. Our study investigates the potential of a multiplex biomarker serum assay to screen high-risk patients for PDAC.
Methods:
High-risk patients prospectively screened in a pancreatic cancer and cyst early detection center were tested with a multiplex biomarker immunoassay between July 2022 and May 2023. Electronic medical records of patients were reviewed.
Results:
Blood samples were collected from 40 patients to be screened using the assay. These included patients with BRCA2 mutations (n=20), IPMN (n=14), IPMN with FPC (n=3), CHEK2 mutation with FPC (n=1), and FPC alone (n=2). High risk signatures were found in six patients with mean CA 19-9 of 112.8 U/mL (SD 169, range 19.3-421.4). Five patients had borderline-risk signatures with mean CA 19-9 levels of 26.1 (SD 12.3, range 18.6-48) and 28 patients had low risk signatures with mean CA 19-9 levels of 10.8 (SD 6.4, range 4.1-29.5). One patient was a CA 19-9 non-producer thus the full assay was not completed per test guidelines. Twelve patients underwent surgery: three with high-risk signature and nine with low-risk signature. From the high-risk signature group, the subsequent surgical pathology found the following: one patient with pancreatic intraepithelial neoplasia 1A (who had a CA 19-9 of 116 and a pancreatic duct stricture) and two patients with stage I PDAC. The first PDAC patient had a CA 19-9 of 367, a biopsy with high-grade dysplasia, and on surgical pathology had a PDAC arising from an IPMN. The second PDAC patient had a CA 19-9 of 421, a biopsy with no dysplasia, and on surgical pathology had a PDAC and a separate invasive IPMN. The other three patients with a high-risk signature had no identifiable abnormality of the pancreas and are undergoing high-intensity surveillance. From the low-risk signature group, two patients had high grade IPMN and seven had low grade IPMN with one having an incidental 3 mm pancreatic neuroendocrine tumor on surgical pathology.
Conclusions:
Among high-risk patients who underwent resection, a multiplex biomarker assay was 100% sensitive and 90% specific for detecting PDAC. The test may identify early cancers not otherwise detected in selected high-risk patients. Further studies and follow-up of high-risk signature patients are needed to validate this use of a multiplex biomarker test as a screening tool.

Tracks

Related Products

Thumbnail for TYPE I CHOLEDOCHAL CYSTS IN ADULTS: NATURAL HISTORY AND IMPLICATIONS FOR MANAGEMENT
TYPE I CHOLEDOCHAL CYSTS IN ADULTS: NATURAL HISTORY AND IMPLICATIONS FOR MANAGEMENT
BACKGROUND: Historical pediatric data recommend surgical resection for type I choledochal cysts due to the risk of malignant progression over time up to 30%…
Thumbnail for ENDOSCOPIC ULTRASOUND (EUS) BETTER PREDICTS TUMOR SIZE AND VASCULAR INVOLVEMENT COMPARED TO CROSS-SECTIONAL IMAGING IN PANCREATIC CANCER
ENDOSCOPIC ULTRASOUND (EUS) BETTER PREDICTS TUMOR SIZE AND VASCULAR INVOLVEMENT COMPARED TO CROSS-SECTIONAL IMAGING IN PANCREATIC CANCER
BACKGROUND: Accurate clinical staging plays a key role in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC)…
Thumbnail for SAVE THE SPLEEN OR FIX IT IN FORMALIN: IS THERE A DIFFERENCE IN PERIOPERATIVE OUTCOME?
SAVE THE SPLEEN OR FIX IT IN FORMALIN: IS THERE A DIFFERENCE IN PERIOPERATIVE OUTCOME?
Splenectomy carries risk of infectious complications. Splenic preservation (SP) avoids these immunologic consequences but is not common surgical practice. When permissible by clinical status and pathology, SP may be acceptable in select patients…